KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024)

Historic Cash from Discontinued Operations for Travere Therapeutics (TVTX) over the last 6 years, with Q4 2024 value amounting to -$7.1 million.

  • Travere Therapeutics' Cash from Discontinued Operations fell 1621.31% to -$7.1 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 970.29%. This contributed to the annual value of -$7.5 million for FY2024, which is 11643.51% down from last year.
  • Per Travere Therapeutics' latest filing, its Cash from Discontinued Operations stood at -$7.1 million for Q4 2024, which was down 1621.31% from $50000.0 recorded in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' Cash from Discontinued Operations peaked at $22.1 million during Q4 2022, and registered a low of -$7.1 million during Q4 2024.
  • Moreover, its 3-year median value for Cash from Discontinued Operations was $50000.0 (2024), whereas its average is $6.7 million.
  • As far as peak fluctuations go, Travere Therapeutics' Cash from Discontinued Operations plummeted by 12764.68% in 2023, and later plummeted by 1621.31% in 2024.
  • Over the past 3 years, Travere Therapeutics' Cash from Discontinued Operations (Quarter) stood at $22.1 million in 2022, then tumbled by 127.65% to -$6.1 million in 2023, then dropped by 16.21% to -$7.1 million in 2024.
  • Its Cash from Discontinued Operations was -$7.1 million in Q4 2024, compared to $50000.0 in Q3 2024 and -$309000.0 in Q2 2024.